Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: retrospective comparative evaluation of clinically axillary lymph node positive and negative patients, including those with axillary lymph node metastases confirmed by fine needle aspiration

BMC Cancer

Research Article

Ning Cui¹  Heng-Yu Li¹  Yan-Mei Wu¹  Yue Yu¹  Lu Xu¹  Min Fang¹  Yuan Sheng¹ 

[1] Department of Breast and Thyroid Surgery, Changhai Hospital, the Second Military Medical University, 168 Changhai Road, Yangpu District, 200433, Shanghai, China;Department of Breast and Thyroid Surgery, Shangqiu First People’s Hospital, Shangqiu, Hernan, China;

关键词: Breast Cancer Patient;    Sentinel Lymph Node;    Sentinel Lymph Node Biopsy;    Axillary Lymph Node;    Axillary Lymph Node Dissection;   

DOI  :  10.1186/s12885-016-2829-5

 received in 2015-11-05, accepted in 2016-10-03,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundTo evaluate the accuracy of sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) in breast cancer patients with axillary lymph node (ALN) metastasis.MethodsA total of 122 patients with operable breast cancer were enrolled in this single-center retrospective study. Eighty patients were clinically diagnosed with a positive axillary lymph node (ALN) via imaging or physical examination (including 66 patients with biopsy-proven metastasis). The other 42 cases had a clinically negative ALN. After four sessions of neoadjuvant chemotherapy, patients were assigned to an ALN-positive or -negative group. The identification rate (IR) and false negative rate (FNR) were determined in the ALN-negative group.ResultsALN changed from positive to negative after NAC in 48 patients. Among them, 46 had at least one SLN resected (total IR = 95.8 %). Eight of the 46 SLN-negative patients had pathologically confirmed metastasis of at least one non-SLN (FNR = 36 %). Fifty-five of the 56 patients with a biopsy-proven negative ALN remained ALN negative. Furthermore, 54 of the 56 patients had at least one SLN resected (IR =98.2 %). Three SLN-negative patients of the 54 had at least one positive non-SLN (FNR = 10.7 %).ConclusionsDue to its high FNR, post-NAC SLNB is not recommended for breast cancer patients with ALN metastasis confirmed by biopsy, though their ALN may become negative after NAC. However, for operable breast cancer with negative ALN, post-NAC SLNB is feasible if the ALN remains clinically negative after NAC.Trial registrationRetrospective evaluation.

【 授权许可】

CC BY   
© The Author(s). 2016